A product of Bayer’s research, the anticoagulant rivaroxaban is expected to provide new treatment options for patients with atrial fibrillation. Our cover photo shows Bayer scientist Dr. Scott D. Berkowitz (right) with Prof. Robert M. Califf from Duke University in North Carolina, United States.